Replimune Group Inc’s recently made public that its Director Astley-Sparke Philip unloaded Company’s shares for reported $0.26 million on May 20 ’25. In the deal valued at $8.06 per share,32,279 shares were sold. As a result of this transaction, Astley-Sparke Philip now holds 1,405,071 shares worth roughly $14.23 million.
Then, Xynos Konstantinos sold 7,952 shares, generating $64,093 in total proceeds. Upon selling the shares at $8.06, the Chief Medical Officer now owns 146,933 shares.
Before that, Schwendenman Andrew sold 3,287 shares. Replimune Group Inc shares valued at $26,460 were divested by the Chief Accounting Officer at a price of $8.05 per share. As a result of the transaction, Schwendenman Andrew now holds 68,284 shares, worth roughly $0.69 million.
ROTH MKM initiated its Replimune Group Inc [REPL] rating to a Buy in a research note published on August 28, 2024; the price target was $17. Piper Sandler began covering REPL with “an Overweight” recommendation on November 19, 2021.
Price Performance Review of REPL
On Tuesday, Replimune Group Inc [NASDAQ:REPL] saw its stock fall -0.49% to $10.13. Over the last five days, the stock has gained 5.19%. Replimune Group Inc shares have fallen nearly -16.35% since the year began. Nevertheless, the stocks have risen 42.48% over the past one year.
How much short interest is there in Replimune Group Inc?
A steep rise in short interest was recorded in Replimune Group Inc stocks on 2025-05-15, growing by 0.39 million shares to a total of 9.22 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 8.83 million shares. There was a rise of 4.27%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 17, 2020 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
